CN113082289A - Composite preparation containing autologous collagen and application thereof - Google Patents
Composite preparation containing autologous collagen and application thereof Download PDFInfo
- Publication number
- CN113082289A CN113082289A CN202110495488.XA CN202110495488A CN113082289A CN 113082289 A CN113082289 A CN 113082289A CN 202110495488 A CN202110495488 A CN 202110495488A CN 113082289 A CN113082289 A CN 113082289A
- Authority
- CN
- China
- Prior art keywords
- layer
- autologous collagen
- collagen
- composite preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 57
- 108010035532 Collagen Proteins 0.000 title claims abstract description 57
- 229920001436 collagen Polymers 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000002131 composite material Substances 0.000 title claims abstract description 22
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 20
- 230000003416 augmentation Effects 0.000 claims abstract description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011575 calcium Substances 0.000 claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 24
- 235000010355 mannitol Nutrition 0.000 claims description 23
- 229930195725 Mannitol Natural products 0.000 claims description 22
- 239000000594 mannitol Substances 0.000 claims description 22
- 238000005119 centrifugation Methods 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 19
- 210000003743 erythrocyte Anatomy 0.000 claims description 19
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 19
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 19
- 238000003860 storage Methods 0.000 claims description 16
- 239000002504 physiological saline solution Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000011026 diafiltration Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 238000010241 blood sampling Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 230000002045 lasting effect Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 210000001331 nose Anatomy 0.000 description 29
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000012528 membrane Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 6
- 229940047670 sodium acrylate Drugs 0.000 description 6
- 230000007547 defect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009260 Cleft lip and palate Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000016653 cleft lip/palate Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000004728 ear cartilage Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002435 rhinoplasty Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composite preparation containing autologous collagen, which comprises calcium hydroxyapatite and autologous collagen. The invention also discloses application of the composite preparation containing the autologous collagen. The composite preparation of the embodiment of the invention is injected into a body, autologous collagen is degraded and absorbed, meanwhile, fibroblast proliferation of the composite preparation can be stimulated, hydroxyapatite calcium is used as a bracket for fibroblast ingrowth to generate new collagen tissues, and the composite preparation of the embodiment of the invention has good biocompatibility, good stability, no wandering property, capability of keeping fixed volume and flexibility, difficult deformation under external force, ideal appearance and hardness of transplanted tissues and lasting nose augmentation effect.
Description
The application is a divisional application with application date of 2018, 08 and 27, application number of 201810978561.7, and invention name of 'a composite preparation containing autologous collagen and application thereof'.
Technical Field
The invention relates to the technical field of shaping and beautifying materials, in particular to a composite preparation containing autologous collagen and application thereof.
Background
With the improvement of social and economic levels and the rapid development of the major cosmetic and plastic professions, the beauty-seeking people have more and more demands on facial beauty. The nose is positioned in the center of the face of a person and is called as the soul of five sense organs, the outline and the stereoscopic impression of the face are directly influenced, the appearance of the nose of an Asian person is lower and flat compared with that of a western person, the nose is more round and blunt, and the nose shaping is carried out in order to have a straight nose. The nose augmentation operation is an operation for reshaping or improving the appearance of the nose, and is suitable for beauty seeking patients with low and flat nasal root or nasal back, round and flat nose, large nostrils, wide nasal base and the like, and patients with nasal collapse, nasal sadness, asymmetric nostrils or cleft lip and palate and the like.
The nose humping mode comprises operation and injection nose humping. The injection nose humping is to inject the filler into the subcutaneous part of the nose, so that the appearance of the skin nose humps and is beautiful, and the injection nose humping is favored by broad medical professionals and beauty lovers due to the advantages of convenient and fast method, no anesthesia, no need of opening a knife, easy shaping, repeatability, follow-up treatment and the like. With the demand for injection humps greatly increasing, more and more types of injection filling materials are used.
Currently, the mainstream augmentation nasal filling materials comprise silica gel, polytetrafluoroethylene, hyaluronic acid and autologous cartilage. Wherein: the silica gel has the advantages of high and low temperature resistance, good chemical stability, corrosion resistance and histocompatibility, no toxicity, no carcinogenesis and no distortion, but has the defects of unfixed property, easy sliding displacement and poor plasticity. Polytetrafluoroethylene is a soft graft material with a micropore structure, has better tissue compatibility than silicone rubber, is easy to shape, has softer material than silicone rubber, has smoother transition between prosthesis and surrounding tissues, has more natural appearance of a nose after operation, is an ideal material for humping the nose and improving the shape of the nose tip part, but has high price, and influences the popularization and the use of the material. Hyaluronic acid is a substance naturally existing in tissues, is one of components of human dermal tissues, has the advantages of safe materials, instant effect, short time and almost no recovery period after operation, but can be slowly absorbed, generally the hyaluronic acid nasal augmentation can be maintained for about 6-12 months, and repeated injection is needed. The autologous cartilage is mostly taken from costal cartilage, nasal septum cartilage and auricular cartilage, has the advantages of no rejection and strong anti-infection capability, and simultaneously has the defects of residual incision scars at the taking-out position of the material and partial absorption.
In view of this, the present disclosure is set forth.
Disclosure of Invention
In order to solve the problems of the prior art, the embodiments of the present invention are directed to providing a complex formulation comprising autologous collagen and applications thereof.
To achieve the above objects, a first aspect of embodiments of the present invention provides a complex formulation comprising autologous collagen, the complex formulation comprising calcium hydroxyapatite and autologous collagen.
Further, the particle size of the calcium hydroxyapatite is 25-45 μm.
Further, the preparation method of the autologous collagen comprises the following steps: blood is collected by a human body through blood collection, the blood enters a whole blood separator after being centrifuged for the first time, secondary centrifugation is carried out in the whole blood separator, the whole blood centrifugation is divided into three layers, a plasma layer, a white membrane layer and a red blood cell layer are sequentially arranged from top to bottom, liquid of the plasma layer, the white membrane layer and the red blood cell layer is respectively led into different storage units through catheters to be separately stored, a proper amount of plasma layer and white membrane layer liquid are taken out from the storage units to be mixed in proportion, preliminary purification is carried out through a chromatography unit, and the required autologous collagen is obtained through further purification of a diafiltration unit.
Further, the preparation method of the compound preparation comprises the following steps: adding hydroxyapatite calcium and autologous collagen into the binder, and uniformly dispersing by ultrasonic waves.
Furthermore, 0.01-0.02g of calcium hydroxyapatite and 0.02-0.06g of autologous collagen are added into each 10ml of the adhesive.
Further, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline in a weight ratio of 1: (1-3): (5-10)
A second aspect of embodiments of the present invention provides a use of the above-described complex formulation comprising autologous collagen for the preparation of a filling material for augmentation rhinoplasty.
The hydroxyapatite calcium is a polymer material containing micropores and forming human bones and teeth, has a larger theoretical density of 3.156g/cm < 3 >, a refractive index of 1.64-1.65 and a Mohs hardness of 5, is slightly soluble in water, is weakly alkaline (pH is 7-9), is easily soluble in acid and is hardly soluble in alkali. A large number of biocompatibility tests prove that the calcium hydroxyapatite can be firmly and chemically combined with bone formation, and has the advantages of good histocompatibility, no need of an allergy test and high viscosity.
The autologous collagen is prepared from autologous collagen which is extracted from human venous blood and is rich in a large number of platelets and collagen, the blood is divided into three layers by centrifugation, a plasma layer mainly comprises plasma, water, protein, salts, various ions and the like, a white membrane layer mainly comprises a platelet-rich area, a lymphocyte-rich area, a monocyte-rich area and a granulocyte-rich area, the erythrocyte layer can be simply divided into young erythrocytes and normal erythrocytes, and the mixed liquid of the extracted plasma layer and the white membrane layer contains a large number of collagen and is rich in platelets and various growth factors, so that after entering a superficial dermis, the autologous collagen, elastic fibers, colloid and the like can be stimulated to generate, and tissues can be regenerated.
Sodium carboxymethyl cellulose is a cellulose derivative with good biocompatibility, and the aqueous solution of the sodium carboxymethyl cellulose has certain viscosity, so that the sodium carboxymethyl cellulose can be used as an adhesive of tablets and a suspending agent of injections.
Mannitol, also known as D-mannitol, is an isomer with sorbitol. It is a non-hygroscopic, odorless, white or colorless crystalline powder. Mannitol, as a hexahydric sugar alcohol, has the characteristics of stable property, no need of insulin for physiological metabolism and the like, and also has unique physiological performance. Mannitol is freely filtered from the glomerulus after entering the body, and the renal tubules have a limited reabsorption mechanism for mannitol, are pharmacologically inactive, are poorly metabolized in the human body, and are not easily accessible to the tissues via the capillaries. After mannitol is injected into a body, mannitol molecules can only flow in blood vessels, so that osmotic gradient is generated between tissues and an intravascular system, liquid is promoted to flow from the tissues to the blood vessels, the osmotic pressure of plasma is rapidly increased, excessive water in the tissues is transferred to the plasma, and then the excessive water is discharged out of the body through a renal excretion system, so that the effects of diuresis and drainage are achieved.
The embodiment of the invention has the following advantages:
according to the embodiment of the invention, calcium hydroxyapatite and autologous collagen are used as filling components of the nose augmentation material, a mixture containing sodium carboxymethylcellulose, mannitol and normal saline is used as a dispersion carrier, the filling components can be stably dispersed in the dispersion carrier for a long time, and the nose augmentation material is convenient to inject, and has the characteristics of moderate degradation time, complete absorption of degradation products, no residue in a human body and high application safety.
The composite preparation provided by the embodiment of the invention is injected into a body, autologous collagen is degraded and absorbed along with the lapse of time, meanwhile, autologous collagen can stimulate the proliferation of fibroblasts, hydroxyapatite calcium is used as a scaffold for the inward growth of the fibroblasts to generate new collagen tissues in situ, and the composite preparation has the advantages of ideal tissue appearance and hardness and lasting nose augmentation effect.
The composite preparation has excellent biocompatibility, no rejection reaction and anaphylactic reaction after being applied to a human body, and is safer and more effective in application.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.012g of calcium hydroxyapatite with particle size of 40 μm and 0.04g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic wave.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 2: 6.
the preparation method of the autologous collagen comprises the following steps: blood is collected by a human body through blood collection, the blood enters a whole blood separator after being centrifuged for the first time, secondary centrifugation is carried out in the whole blood separator, the whole blood centrifugation is divided into three layers, namely a plasma layer, a white membrane layer and a red blood cell layer from top to bottom, the liquids of the plasma layer, the white membrane layer and the red blood cell layer are respectively led into different storage units through guide tubes to be stored separately, a proper amount of the liquids of the plasma layer and the white membrane layer are taken out from the storage units to be mixed according to the ratio of 1:1, and the liquids are subjected to primary purification through a chromatography unit and further purified through a diafiltration unit to obtain the required autologous collagen.
Example 2
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.015g of hydroxyapatite calcium with the particle size of 25 mu m and 0.036g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic waves.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 3: 8.
the preparation method of the autologous collagen comprises the following steps: blood is collected by a human body through blood collection, the blood enters a whole blood separator after being centrifuged for the first time, secondary centrifugation is carried out in the whole blood separator, the whole blood centrifugation is divided into three layers, namely a plasma layer, a white membrane layer and a red blood cell layer from top to bottom, the liquids of the plasma layer, the white membrane layer and the red blood cell layer are respectively led into different storage units through guide tubes to be stored separately, a proper amount of the liquids of the plasma layer and the white membrane layer are taken out from the storage units to be mixed according to the ratio of 1:1, and the liquids are subjected to primary purification through a chromatography unit and further purified through a diafiltration unit to obtain the required autologous collagen.
Example 3
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.01g of calcium hydroxyapatite with the particle size of 35 mu m and 0.06g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic waves.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 2: 7.
the preparation method of the autologous collagen comprises the following steps: blood is collected by a human body through blood collection, the blood enters a whole blood separator after being centrifuged for the first time, secondary centrifugation is carried out in the whole blood separator, the whole blood centrifugation is divided into three layers, namely a plasma layer, a white membrane layer and a red blood cell layer from top to bottom, the liquids of the plasma layer, the white membrane layer and the red blood cell layer are respectively led into different storage units through guide tubes to be stored separately, a proper amount of the liquids of the plasma layer and the white membrane layer are taken out from the storage units to be mixed according to the ratio of 1:1, and the liquids are subjected to primary purification through a chromatography unit and further purified through a diafiltration unit to obtain the required autologous collagen.
Example 4
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.02g of hydroxyapatite calcium with the particle size of 45 mu m and 0.02g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic waves.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 3: 10.
the preparation method of the autologous collagen comprises the following steps: blood sampling is carried out to the human body through the blood sampling, and blood gets into the whole blood separator after centrifugation for the first time to carry out the secondary centrifugation in the whole blood separator, the whole blood centrifugation divide into the three-layer, and top-down is plasma layer, leucoderma layer and red blood cell layer in proper order, and the liquid with plasma layer, leucoderma layer and red blood cell layer is separately deposited through the different storage unit of pipe introduction respectively, takes out proper amount plasma layer and leucoderma layer liquid by the storage unit and according to 1:1, mixing, performing primary purification by a chromatography unit, and further purifying by a diafiltration unit to obtain the required autologous collagen.
Example 5
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.011g of calcium hydroxyapatite with the particle size of 30 mu m and 0.05g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic waves.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 1: 5.
the preparation method of the autologous collagen comprises the following steps: blood sampling is carried out to the human body through the blood sampling, and blood gets into the whole blood separator after centrifugation for the first time to carry out the secondary centrifugation in the whole blood separator, the whole blood centrifugation divide into the three-layer, and top-down is plasma layer, leucoderma layer and red blood cell layer in proper order, and the liquid with plasma layer, leucoderma layer and red blood cell layer is separately deposited through the different storage unit of pipe introduction respectively, takes out proper amount plasma layer and leucoderma layer liquid by the storage unit and according to 1:1, mixing, performing primary purification by a chromatography unit, and further purifying by a diafiltration unit to obtain the required autologous collagen.
Example 6
The preparation method of the composite preparation containing autologous collagen of the embodiment comprises the following steps: adding 0.015g of hydroxyapatite calcium with the particle size of 45 mu m and 0.045g of autologous collagen into 10ml of sodium acrylate, and uniformly dispersing by ultrasonic waves.
Wherein, the binder comprises sodium carboxymethylcellulose, mannitol and physiological saline, and the weight ratio of the sodium carboxymethylcellulose to the mannitol to the physiological saline is 1: 2: 5.
the preparation method of the autologous collagen comprises the following steps: blood sampling is carried out to the human body through the blood sampling, and blood gets into the whole blood separator after centrifugation for the first time to carry out the secondary centrifugation in the whole blood separator, the whole blood centrifugation divide into the three-layer, and top-down is plasma layer, leucoderma layer and red blood cell layer in proper order, and the liquid with plasma layer, leucoderma layer and red blood cell layer is separately deposited through the different storage unit of pipe introduction respectively, takes out proper amount plasma layer and leucoderma layer liquid by the storage unit and according to 1:1, mixing, performing primary purification by a chromatography unit, and further purifying by a diafiltration unit to obtain the required autologous collagen.
Test examples
In order to demonstrate that the complex formulation of the present invention has a good nasal augmentation effect, the present invention conducted the following efficacy test.
1. General data
60 nasal patients who voluntarily receive nose augmentation in the mechanism in 5 months-2017 months in 2015 are selected as study objects, all patients have good health conditions and no other systemic diseases, and informed consent is signed before nose augmentation. Patients were randomized into trial 1-6 groups of 10 cases each, with trial 1 group: male 2 cases, female 8 cases, age 28 ± 8.2 years; test 2 groups: 3 cases in men, 7 cases in women, age 29 ± 7.6 years; run 3 groups: 2 cases in men, 8 cases in women, age 28 ± 7.0 years; run 4 groups: 1 male, 9 female, age 30 ± 6.8 years old; run 5 groups: 4 cases in men, 6 cases in women, age 29 ± 8.0 years; test 6 groups: male 2 cases, female 8 cases, age 27 ± 8.7 years. The patients in each group have no obvious difference in general data such as sex, age and the like, and have no statistical significance (P > 0.05).
2. Method of treatment
The injection hump nose adopts a tunnel injection method, namely, the injection hump nose is pushed while retreating after the needle is inserted, and the needle is pulled out without bringing the injection hump nose to the superficial layer of the dermis; the force is uniform and constant thumb pressure is maintained. Direct injection is required at the correct level of the skin, at 3 different levels, deep dermis, superficial subcutaneous layer and extraperiosteum.
Tests 1-6 the composite preparations prepared in examples 1-6 of the present invention were used for injection at a dose of 2 + -0.5 ml, and were fixed locally for 24 hours after injection.
3. Criteria for therapeutic effect
The effect is shown: after injection, the patient has very satisfactory nasal appearance and positive lateral effect, the nasal part has perfect continuity, and the naked eye has no visible defects.
The method has the following advantages: after injection, the shape of the nose is changed, such as the nasal root is raised, the nasal tip is rounded, but the defects of visual inspection, such as the misnormal axis of the middle nose and the discontinuous nasal line, still exist.
And (4) invalidation: the appearance of the nose is not changed before and after injection, and complications such as infection bleeding and the like appear after operation.
4. Results
After injection, at follow-up 12 months, the results of the treatment effect of the test groups 1-6 are shown in Table 1.
TABLE 1
| Group of | Show effect | Is effective | Invalidation | Total effective rate |
| Test 1 group | 6 | 4 | 0 | 100％ |
| Test 2 groups | 5 | 4 | 1 | 90％ |
| Test 3 groups | 7 | 3 | 0 | 100％ |
| Test 4 groups | 5 | 5 | 0 | 100％ |
| Test 5 groups | 6 | 3 | 1 | 90％ |
| Test 6 groups | 5 | 4 | 1 | 90％ |
The total effective rate of the test group reaches more than 90 percent, and the composite preparation of the embodiment of the invention has good biocompatibility, good stability, no wandering property, fixed volume and flexibility, difficult deformation under external force, ideal tissue appearance and hardness after transplantation and lasting nose augmentation effect.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (2)
1. A composite preparation comprising autologous collagen, wherein the composite preparation comprises calcium hydroxyapatite and autologous collagen;
the particle size of the hydroxyapatite calcium is 35 mu m;
the preparation method of the compound preparation comprises the following steps: adding hydroxyapatite calcium and autologous collagen into the binder, and uniformly dispersing by ultrasonic waves;
0.01g of hydroxyapatite calcium and 0.06g of autologous collagen are added into each 10ml of the adhesive;
the binder comprises sodium carboxymethyl cellulose, mannitol and physiological saline, wherein the weight ratio of the sodium carboxymethyl cellulose to the mannitol to the physiological saline is 1: 2: 7;
the preparation method of the autologous collagen comprises the following steps: blood sampling, blood gets into the whole blood separator after centrifugation for the first time to carry out the centrifugation of secondary in the whole blood separator, the whole blood centrifugation divide into the three-layer, and top-down is plasma layer, leucocyte layer and erythrocyte layer in proper order, and the liquid with plasma layer, leucocyte layer and erythrocyte layer is separately deposited through the different storage unit of pipe introduction respectively, takes out proper amount plasma layer and leucocyte layer liquid by the storage unit and according to 1:1, mixing, performing primary purification by a chromatography unit, and further purifying by a diafiltration unit to obtain the required autologous collagen.
2. Use of the complex formulation comprising autologous collagen according to claim 1 for the preparation of a material for nasal augmentation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110495488.XA CN113082289A (en) | 2018-08-27 | 2018-08-27 | Composite preparation containing autologous collagen and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978561.7A CN109078220A (en) | 2018-08-27 | 2018-08-27 | A kind of compound formulation comprising autologous collagen albumen and its application |
| CN202110495488.XA CN113082289A (en) | 2018-08-27 | 2018-08-27 | Composite preparation containing autologous collagen and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978561.7A Division CN109078220A (en) | 2018-08-27 | 2018-08-27 | A kind of compound formulation comprising autologous collagen albumen and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113082289A true CN113082289A (en) | 2021-07-09 |
Family
ID=64794698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978561.7A Pending CN109078220A (en) | 2018-08-27 | 2018-08-27 | A kind of compound formulation comprising autologous collagen albumen and its application |
| CN202110495488.XA Withdrawn CN113082289A (en) | 2018-08-27 | 2018-08-27 | Composite preparation containing autologous collagen and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978561.7A Pending CN109078220A (en) | 2018-08-27 | 2018-08-27 | A kind of compound formulation comprising autologous collagen albumen and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109078220A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169879A (en) * | 1996-07-09 | 1998-01-14 | 王革生 | Filling injection material for cosmetic face-lifting |
| CN102492032A (en) * | 2011-11-16 | 2012-06-13 | 陕西巨子生物技术有限公司 | Human-like collagen and injectable human-like collagen soft-tissue filling material |
| CN102580056A (en) * | 2011-12-16 | 2012-07-18 | 深圳市健元医药科技有限公司 | Controlled-release injection containing antidiuresis components and preparation method thereof |
| US9144434B1 (en) * | 2010-09-29 | 2015-09-29 | Rodan & Fields, Llc | Methods and compositions for treating skin |
| CN105555250A (en) * | 2013-08-05 | 2016-05-04 | 波利化学公司 | Composition for skin anti-ageing treatment |
| CN106492276A (en) * | 2016-11-28 | 2017-03-15 | 北京奥精医药科技有限公司 | A kind of injectable beauty and shaping material and preparation method thereof |
| CN108341865A (en) * | 2018-05-18 | 2018-07-31 | 白晋 | A kind of novel equipment and method for preparing collagen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285427B (en) * | 2013-04-26 | 2014-11-05 | 中国国旅贸易有限责任公司 | Artificial bone material and preparation method thereof |
-
2018
- 2018-08-27 CN CN201810978561.7A patent/CN109078220A/en active Pending
- 2018-08-27 CN CN202110495488.XA patent/CN113082289A/en not_active Withdrawn
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1169879A (en) * | 1996-07-09 | 1998-01-14 | 王革生 | Filling injection material for cosmetic face-lifting |
| US9144434B1 (en) * | 2010-09-29 | 2015-09-29 | Rodan & Fields, Llc | Methods and compositions for treating skin |
| CN102492032A (en) * | 2011-11-16 | 2012-06-13 | 陕西巨子生物技术有限公司 | Human-like collagen and injectable human-like collagen soft-tissue filling material |
| CN102580056A (en) * | 2011-12-16 | 2012-07-18 | 深圳市健元医药科技有限公司 | Controlled-release injection containing antidiuresis components and preparation method thereof |
| CN105555250A (en) * | 2013-08-05 | 2016-05-04 | 波利化学公司 | Composition for skin anti-ageing treatment |
| CN106492276A (en) * | 2016-11-28 | 2017-03-15 | 北京奥精医药科技有限公司 | A kind of injectable beauty and shaping material and preparation method thereof |
| CN108341865A (en) * | 2018-05-18 | 2018-07-31 | 白晋 | A kind of novel equipment and method for preparing collagen |
Non-Patent Citations (1)
| Title |
|---|
| 孔祥峰等: "微晶瓷注射隆鼻术研究进展及并发症防治", 《中国医疗美容》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109078220A (en) | 2018-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11992580B2 (en) | Method of soft tissue augmentation | |
| RU2671837C2 (en) | Method for obtaining injectable hydrogel based on hyaluronic acid containing lidocaine added in powder form, and alkaline agent, sterilised with heat | |
| US7790194B2 (en) | Polyacrylamide hydrogel as a soft tissue filler endoprosthesis | |
| CN111249189B (en) | An injectable facial filler composition for skin care and plastic, and its preparation method | |
| KR102452905B1 (en) | the method for skin improvement cosmetic composition containing natural spicule and polydioxanone and the cosmetic composition thereof | |
| CN111282015B (en) | Artificial skin scar removing plaster | |
| CN106074213A (en) | Hyaluronic acid sodium gel for water optoinjection and its preparation method and application | |
| CN110279888A (en) | A kind of injection Ago-Gel agent and preparation method thereof | |
| EP2945612B1 (en) | Increasing muscular volume in a human using hyaluronic acid | |
| CN113456807A (en) | Soft tissue filler and application thereof | |
| CN113082289A (en) | Composite preparation containing autologous collagen and application thereof | |
| KR20120140450A (en) | Composition for promoting the differentiation of human mesenchymal stem cell | |
| CN111973806A (en) | Composition and application thereof | |
| CN110327366A (en) | A kind of beauty pharmaceutical composition containing sodium hyaluronate | |
| RU2659959C1 (en) | Composition of the preparation for correction of skin defects | |
| US11369718B1 (en) | Method and use of cryopreserved mesenchymal stem cells via liquid suspension from the amniotic sac for rejuvenation of the midface | |
| Zhang et al. | Application of Arm Infusion Port, Chest Wall Infusion Port and PICC in Chemotherapy of Blood Tumor. | |
| Kaufman | Microfat grafting: the nurse's role | |
| Schonauer et al. | Staggered wedge technique for ear reconstruction | |
| KR20130041103A (en) | Method for preparing dermis tissue cells aggregation and uses thereof | |
| CN115364358A (en) | Positive healing technology of small facial needles | |
| Nahai | Update on radiofrequency ablation of the frontal branch to the corrugator muscles to reduce glabellar frown lines | |
| CN114869912A (en) | A kind of preparation method of human mesenchymal stem cell composite nPRF preparation | |
| CN113462643A (en) | Culture medium for mesenchymal stem cells of hair follicle and preparation method thereof | |
| CN111035808A (en) | Method for improving perineum fat filling effect by using autologous adipose-derived stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210709 |
|
| WW01 | Invention patent application withdrawn after publication |